CELESTICA INC

China’s 4 Sep market: tech, nickel, securities and pharma lead gains, amid supply‑chain, regulatory and scalability risks.

CELESTICA INC raises ¥45 bn to boost mRNA LNP tech, targeting rare diseases and fast‑track approvals amid China’s biotech boom.

Medical‑device boom: how 3‑nm ASICs, 3‑D packaging and software‑defined edge AI are driving Nasdaq biotech gains and reshaping clinical workflows.

Celestica’s 2,000‑person Malaysia expansion aims to boost AI‑enabled data‑centre capacity, yet faces talent, supply‑chain, and profitability risks that could shape its future market share.

Celestica’s 2026 SEC filing shows no‑consideration RSU grants that vest by 2027–2029, aligning CEO and board pay with long‑term EMS growth and investor confidence.

Celestica Q1 2026: modest revenue growth, margin expansion from PCB automation and advanced materials, and disciplined capital spending fuel future gains.

Explore how active ETF trends shape semiconductor and biotech hardware, revealing the trade‑offs between performance, yield, and supply‑chain resilience.

China’s July 20, 2026 rally shows tech‑sectors thriving—biopharma and semiconductors gain, new hybrid ETFs attract strong inflows.

China’s first actively‑managed ETFs unveil a low‑turnover, diversified strategy, blending active skill with ETF liquidity for long‑term investors.

China’s CSRC launches 18 actively‑managed ETFs, blending liquidity, transparency and alpha‑seeking strategies—unlocking new growth for A‑share investors.